Harmony Biosciences Holdings (HRMY) Receivables (2019 - 2026)

Harmony Biosciences Holdings (HRMY) has 8 years of Receivables data on file, last reported at $108.2 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables rose 2.13% year-over-year to $108.2 million; the trailing twelve-month figure through Mar 2026 stood at $108.2 million (up 2.13% YoY), and the FY2025 full-year result was $96.8 million, up 16.56% from the prior year.
• Receivables improved to $108.2 million in Q1 2026, from $96.8 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $108.2 million in Q1 2026 to a low of $38.1 million in Q1 2022.
• A 5-year average of $75.7 million and a median of $79.7 million in 2024 frame the typical range for Receivables.
• Across the five-year window, Receivables surged 65.83% in 2022 and grew 2.13% in 2026, its largest moves.
• Tracing HRMY's Receivables over 5 years: stood at $54.7 million in 2022, then surged by 35.44% to $74.1 million in 2023, then grew by 11.99% to $83.0 million in 2024, then rose by 16.56% to $96.8 million in 2025, then rose by 11.81% to $108.2 million in 2026.
• Business Quant data shows HRMY's Receivables at $108.2 million in Q1 2026, $96.8 million in Q4 2025, and $100.7 million in Q3 2025.